购物车
全部删除
您的购物车当前为空
别名 dipeptidylpeptidase 4
Anti-DPP4/CD26 Antibody-FITC (6M894) 是一种 FITC-conjugated Mouse 抗体,靶向 DPP4/CD26。Anti-DPP4/CD26 Antibody-FITC (6M894) 可用于 FCM。
Anti-DPP4/CD26 Antibody-FITC (6M894) 是一种 FITC-conjugated Mouse 抗体,靶向 DPP4/CD26。Anti-DPP4/CD26 Antibody-FITC (6M894) 可用于 FCM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 T | ¥ 685 | 5日内发货 | |
| 100 T | ¥ 1,490 | 5日内发货 |
| 产品描述 | Anti-DPP4/CD26 Antibody-FITC (6M894) is a FITC-conjugated Mouse antibody targeting DPP4/CD26. Anti-DPP4/CD26 Antibody-FITC (6M894) can be used in FCM. |
| 别名 | dipeptidylpeptidase 4 |
| Ig Type | Mouse IgG1 |
| 克隆号 | 6M894 |
| 交叉反应 | Human |
| 特异性 | Human DPP-4/CD26/DPPIV |
| 验证活性 | Flow cytometric analysis of Human CD26(DPP4) expression on human whole blood lymphocytes. Cells were stained with FITC-conjugated anti-Human CD26(DPP4). The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes. |
| 应用 | FCM |
| 推荐剂量 | 10 μl/Test, 0.1 mg/ml |
| 抗体种类 | Monoclonal |
| 宿主来源 | Mouse |
| 构建方式 | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human DPP4 / CD26 (rh DPP4 / CD26; TMPY-00779; NP_001926.2; Asn29-Pro766) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| 纯化方式 | Protein A |
| 性状 | Liquid |
| 缓冲液 | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| 研究背景 | Dipeptidyl peptidase-4 (DPP4) or adenosine deaminase complexing protein 2 (ADCP 2) or T-cell activation antigen CD26 is a serine exopeptidase belonging to the S9B protein family that cleaves X-proline dipeptides from the N-terminus of polypeptides, such as chemokines, neuropeptides, and peptide hormones. The enzyme is a type II transmembrane glycoprotein, expressed on the surface of many cell types. It is also present in serum and other body fluids in a truncated form (sCD26/DPPIV). The soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. As both a regulatory enzyme and a signalling factor, DPP4 has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA(1c)) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development, and are a new pharmacological class of drugs for treating Type 2 diabetes. |
| 偶联 | FITC |
| 其他可选修饰符 | Unconjugated/APC/PE |
| 可提供抗体种类 | 4 |
| 免疫原 | Recombinant Protein: Human DPP4 / CD26 protein (TMPY-00779) |
| 抗原种属 | Human |
| 研究领域 | Serine Proteases and Regulators |
| 储存方式 | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. |
| 运输方式 | Shipping with blue ice. |
评论内容